Bioprocess Technology Market Report 2025

The bioprocess technology market size has grown rapidly in recent years. It will grow from $25.08 billion in 2024 to $29.01 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to biopharmaceutical industry growth, rising chronic diseases, regulatory support, increasing research and development activities, globalization of biopharmaceutical production.

The bioprocess technology market size is expected to see rapid growth in the next few years. It will grow to $52.94 billion in 2029 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to emergence of single-use bioprocessing, cell and gene therapies, bioprocessing for sustainable practices, increasing outsourcing of bioprocessing services, global pandemic preparedness. Major trends in the forecast period include single-use bioprocessing, continuous bioprocessing, advanced analytics and process monitoring, personalized medicine and cell therapies, strategic collaborations and partnerships, gene editing technologies.

The increasing demand from healthcare industries is expected to drive the growth of the bioprocess technology market in the coming years. Healthcare industries encompass companies and organizations that provide medical and healthcare-related products, services, and technologies. Bioprocess technology utilizes living cells, such as those derived from bacteria or mammals, to produce therapeutic proteins, vaccines, and other biologics that aid in the manufacturing of biopharmaceuticals and other healthcare products. For example, in 2022, the Office for National Statistics, a UK-based national statistics organization, reported that healthcare expenditure in the UK reached approximately $354.88 billion (£283 billion), marking a nominal increase of 0.7% compared to 2021. Thus, the growing demand from healthcare industries is propelling the bioprocess technology market's growth.

The rising prevalence of chronic diseases is anticipated to further fuel the growth of the bioprocess technology market. Chronic diseases, lasting three months or more and potentially worsening over time, are a significant focus for bioprocess technology. The technology contributes to the development and production of gene therapies, vaccines, cell culture and fermentation, and monoclonal antibody production aimed at addressing chronic diseases, thereby advancing medicine and enhancing the quality of life for individuals. According to the National Library of Medicine, the number of people in the U.S. aged 50 and older with at least one chronic condition is projected to increase by 99.5% to 142.66 million by 2050. Additionally, the World Health Organization (WHO) reported in September 2022 that 74% of all deaths globally are caused by noncommunicable diseases (NCDs) or chronic diseases, amounting to 41 million deaths annually. The increasing prevalence of chronic diseases is a significant driver for the growth of the bioprocess technology market.

Major companies in the bioprocess technology market are adopting innovative technological products, exemplified by the introduction of Livit Flex, to gain a competitive edge. Livit Flex, launched by Getinge, a Sweden-based healthcare company in December 2022, is an intuitive system for bioprocess control designed to accelerate research and development (R&D) processes for pharmaceuticals and biotech products. Livit Flex offers flexibility, customization, simplicity, and time and cost-efficiency for process optimization. Equipped with smart sensor technology and easy-to-use software functionalities, it enables users to quickly set up parallel experiments and monitor all data from one central location. Configured for single or dual control systems for single-use or multi-use bioreactors, Livit Flex optimizes laboratory bench space. This focus on technological innovation is contributing to the competitive advantage of major companies in the bioprocess technology market.

Prominent companies in the bioprocess technology market are actively pursuing innovation in technological advancements, exemplified by the introduction of the custom organoid line expansion service, to secure a competitive edge. The custom organoid line expansion service involves utilizing proprietary bioreactor and bioprocess technology to scale up the production of organoids. Molecular Devices LLC, a US-based research and development company, launched the custom organoid line expansion service in July 2023. This service is designed to assist researchers in screening thousands to tens of thousands of drug candidates in parallel on organoids from the same source. It plays a crucial role in supporting next-generation drug discovery research, enabling the development of more efficient, reproducible, and scalable patient-derived organoids (PDOs).

In September 2023, Repligen Corporation, a US-based company focused on developing and producing materials for the manufacture of biological drugs, acquired Metenova Corporation for an undisclosed amount. This acquisition aims to expand Repligen Corporation's product offerings and enhance its position in the bioprocess market. Metenova, based in Sweden, is an innovator and manufacturer of bottom-mounted magnetic mixers designed for use in the pharmaceutical and biotechnology sectors.

Major companies operating in the bioprocess technology market include Sartorius AG, Thermo Fisher Scientific Inc., Lonza Group AG, F. Hoffmann-La Roche Ltd., Becton Dickinson and Company, Merck KGa, GE Healthcare, Eppendorf AG, Bio-Rad Laboratories, Alere Inc., Fujifilm Healthcare Americas Corporation, Catalent Inc., Asahi Kasei Medical America Inc., Advanced Instruments LLC, Nova Biomedical Corporation, MilliporeSigma, Repligen Corporation, Danaher Corporation, PerkinElmer Inc., Applikon Biotechnology, New Brunswick Scientific Co. Inc., Avid Bioservices, ZETA Holding GmbH, Meissner Filtration Products, ABL Europe, ARTeSYN Biosolutions, Charles River Laboratories, Parker Hannifin Corporation, Shimadzu Corporation, 3M, Eppendorf Biochip Systems, Fermenter Bioreactor, YMC Europe GmbH, Solaris Biotechnology Srl, Aber Instruments, Cytiva.

North America was the largest region in the bioprocess technology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the bioprocess technology market report during the forecast period. The regions covered in the bioprocess technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioprocess technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bioprocessing technology involves the creation of biological products such as medications, chemicals, and biofuels through living organisms such as bacteria, yeast, and cells. This technology is instrumental in producing pharmaceuticals, nutritional supplements, flavors, fuels, and chemicals, utilizing biocatalysts such as enzymes or microorganisms within a bioreactor.

The primary categories of bioprocess technologies include cell culture, cell expansion, flow cytometry, cell line development, and virus infiltration. Cell culture denotes the controlled growth and preservation of cells in a laboratory setting, often utilizing bioprocessing techniques to manufacture biologics at scale for research, clinical investigations, and commercial applications. These technologies find diverse applications in biopharmaceuticals, specialty products, industrial chemicals, and environmental management, and cater to a range of end-users such as hospitals, research laboratories, and medical institutions.

The bioprocess technology market research report is one of a series of new reports that provides bioprocess technology market statistics, including bioprocess technology industry global market size, regional shares, competitors with a bioprocess technology market share, detailed bioprocess technology market segments, market trends, and opportunities, and any further data you may need to thrive in the bioprocess technology industry. This bioprocess technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bioprocess technology market consists of revenues earned by entities by providing biologics safety testing, and tangential flow filtration. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprocess technology market also includes sales of instruments, consumables, and accessories that include bioprocess analyzers, osmometers, incubators, and bioreactors used in bioprocessing technology services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.